Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.64 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.62 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.55 |
| ▸ | TP53 | P04637 | 2/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.53 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | CKS1B | P61024 | 1/20 | 0.53 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.53 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | CA1 | P00915 | 3/20 | 0.52 |
| ▸ | CA2 | P00918 | 3/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | CA12 | O43570 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3933575 | 0.89 | CYP4A11 (0.70) | CYP4A11CYP4F2LOXL2ALDH1A1TP53 | |
| SCHEMBL2442432 | 0.88 | NPC1 (0.66) | CYP4A11ALDH1A1MAPTLMNANPC1 | |
| SCHEMBL4238755 | 0.88 | MEN1 (0.59) | CYP4A11CYP4F2LOXL2ALDH1A1CYP2C9 | |
| SCHEMBL1643935 | 0.87 | CYP4A11 (0.66) | CYP4A11CYP4F2LOXL2ALDH1A1TP53 | |
| SCHEMBL10661898 | 0.86 | CYP4A11 (0.69) | CYP4A11CYP4F2LOXL2ALDH1A1TP53 | |
| SCHEMBL70185 | 0.86 | CYP4A11 (0.75) | CYP4A11CYP4F2LOXL2ALDH1A1TP53 | |
| SCHEMBL2499088 | 0.85 | CYP4A11 (0.64) | CYP4A11CYP4F2LOXL2ALDH1A1TP53 | |
| SCHEMBL661620 | 0.85 | CYP4A11 (0.64) | CYP4A11CYP4F2LOXL2ALDH1A1TP53 | |
| SCHEMBL23582799 | 0.84 | LOXL2 (0.62) | CYP4A11CYP4F2LOXL2ALDH1A1TP53 | |
| SCHEMBL14157135 | 0.84 | CYP4A11 (0.62) | CYP4A11CYP4F2LOXL2ALDH1A1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 101 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2013164856-A1 | A PROCESS FOR PREPARING INTERMEDIATES OF 10-PROPARGYL-10-DEAZAAMINOPTERIN (PRALATREXATE) SYNTHESIS AND THE INTERMEDIATES THEREOF | AVRA LABORATORIES PRIVATE LIMITED (IN) | 2013-11-07 | — | — | WO | claimed |
| CN-111655700-B | Oxadiazolopyridine derivatives as ghrelin O-acyltransferase (GOAT) inhibitors | 勃林格殷格翰国际有限公司 | 2023-07-18 | — | — | CN | disclosed |
| EP-3746451-B1 | BENZYL-, (PYRIDIN-3-YL)METHYL- OR (PYRIDIN-4-YL)METHYL-SUBSTITUTED OXADIAZOLOPYRIDINE DERIVATIVES AS GHRELIN O-ACYL TRANSFERASE (GOAT) INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2023-07-12 | — | — | EP | disclosed |
| EP-3746451-B1 | BENZYL-, (PYRIDIN-3-YL)METHYL- OR (PYRIDIN-4-YL)METHYL-SUBSTITUTED OXADIAZOLOPYRIDINE DERIVATIVES AS GHRELIN O-ACYL TRANSFERASE (GOAT) INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2023-07-12 | — | — | EP | disclosed |
| CN-110023309-B | Indazole derivatives as glucagon receptor antagonists | 詹森药业有限公司 | 2022-08-09 | — | — | CN | disclosed |
| CN-109923109-B | Indazole derivatives as glucagon receptor antagonists | 詹森药业有限公司 | 2022-06-17 | — | — | CN | disclosed |
| US-11254688-B2 | Benzyl-, (pyridin-3-yl)methyl -or (pyridin-4-yl)-methyl-substituted oxadiazolopyridine derivatives as ghrelin O-acyl transferase (GOAT) inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2022-02-22 | — | — | US | disclosed |
| US-11254688-B2 | Benzyl-, (pyridin-3-yl)methyl -or (pyridin-4-yl)-methyl-substituted oxadiazolopyridine derivatives as ghrelin O-acyl transferase (GOAT) inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2022-02-22 | — | — | US | disclosed |
| US-20210300878-A1 | CONTRAST AGENTS FOR MYOCARDIAL PERFUSION IMAGING | LANTHEUS MEDICAL IMAGING, INC. (US) | 2021-09-30 | — | — | US | disclosed |
| EP-3385253-B1 | CONTRAST AGENTS FOR MYOCARDIAL PERFUSION IMAGING | LANTHEUS MEDICAL IMAGING INC (US) | 2021-04-07 | — | — | EP | disclosed |
| EP-0006735-B1 | SECONDARY AMINES, THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USE | BEECHAM GROUP PLC (GB) | 1983-06-15 | — | — | EP | disclosed |
| US-4385066-A | DIETETICS, HYPERGLYCEMIC AGENTS ANTIINFLAMMATORY AGENTS | BEECHAM GROUP LIMITED (GB) | 1983-05-24 | — | — | US | disclosed |
| EP-0021636-B1 | SECONDARY AMINES, THEIR PREPARATION AND USE IN PHARMACEUTICAL COMPOSITIONS | BEECHAM GROUP PLC (GB) | 1982-12-01 | — | — | EP | disclosed |
| EP-0007204-B1 | PHENETHANOLAMINES, THEIR FORMULATIONS, USE AND PREPARATION | ELI LILLY AND COMPANY (US) | 1982-11-24 | — | — | EP | disclosed |
| US-4329358-A | 3-Chlorophenyl anti-obesity agents | BEECHAM GROUP LIMITED (GB) | 1982-05-11 | — | — | US | disclosed |
| EP-0040915-A1 | Arylethanolamine derivatives, their preparation and use in pharmaceutical compositions | BEECHAM GROUP PLC (GB) | 1981-12-02 | — | — | EP | disclosed |
| EP-0028105-A1 | Secondary amines, their preparation and use in pharmaceutical compositions | BEECHAM GROUP PLC (GB) | 1981-05-06 | — | — | EP | disclosed |
| EP-0021636-A1 | Secondary amines, their preparation and use in pharmaceutical compositions | BEECHAM GROUP PLC (GB) | 1981-01-07 | — | — | EP | disclosed |
| EP-0007204-A1 | Phenethanolamines, their formulations, use and preparation | ELI LILLY AND COMPANY (US) | 1980-01-23 | — | — | EP | disclosed |
| EP-0006735-A1 | Secondary amines, their preparation, pharmaceutical compositions containing them and their use | BEECHAM GROUP PLC (GB) | 1980-01-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11254688-B2 | Benzyl-, (pyridin-3-yl)methyl -or (pyridin-4-yl)-methyl-substituted oxadiazolopyridine derivatives as ghrelin O-acyl transferase (GOAT) inhibitors | MBOAT4, ADIPOR1, GIPR | CYP4A11 1530/4885CYP4F2 572/4885LOXL2 1394/4885 |
| US-20210300878-A1 | CONTRAST AGENTS FOR MYOCARDIAL PERFUSION IMAGING | TNNI3, TNNT2, FABP3 | CYP4A11 4708/4885CYP4F2 3563/4885LOXL2 2686/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.